BioNTech (BNTX) vs Jazz Pharmaceuticals (JAZZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed BioNTech (BNTX) over the past year, gaining 68.4% versus a loss of 10.2%. Over five years, JAZZ leads with a +64.3% price change compared with -61.5% for BNTX. BioNTech is the larger company by market cap ($23.93 billion vs $15.01 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | JAZZ |
|---|---|---|
| Share price | $95.25 | $231.19 |
| Market cap | $23.93B | $15.01B |
| 1-day change | -0.50% | -0.09% |
| YTD return | +0.05% | +35.99% |
| 1-year return | -10.19% | +68.36% |
| 5-year return | -61.54% | +64.31% |
| P/E ratio (TTM) | — | 15.85 |
| Forward P/E | — | 8.93 |
| EPS (TTM) | $-7.83 | $14.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $4.27B |
| Revenue growth (YoY) | — | +4.88% |
| Net income (latest FY) | — | $-356.15M |
| Operating margin | — | -10.08% |
| Net margin | — | -8.35% |
| 52-week high | $124.00 | $266.38 |
| 52-week low | $79.52 | $128.80 |
| Distance from 52-week high | -23.19% | -13.21% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +21.56% | +27.38% |
| Average volume | 1.15M | 850.55K |
| Shares outstanding | 251.20M | 64.91M |
| Employees | 7,807 | 2,890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JAZZ has outperformed BNTX by 78.6 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
BNTX vs JAZZ FAQ
Which is bigger, BioNTech or Jazz Pharmaceuticals?
BioNTech (BNTX) is larger, with a market capitalization of $23.93B compared with $15.01B for Jazz Pharmaceuticals (JAZZ).
Which stock has performed better over the past year, BNTX or JAZZ?
JAZZ returned +68.36% over the past 12 months, compared with -10.19% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Jazz Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioNTech and Biotechnology: Pharmaceutical Preparations for Jazz Pharmaceuticals.